Jan Stenvang

8.8k total citations · 1 hit paper
93 papers, 5.4k citations indexed

About

Jan Stenvang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jan Stenvang has authored 93 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 43 papers in Oncology and 30 papers in Cancer Research. Recurrent topics in Jan Stenvang's work include Cancer therapeutics and mechanisms (20 papers), MicroRNA in disease regulation (18 papers) and Drug Transport and Resistance Mechanisms (12 papers). Jan Stenvang is often cited by papers focused on Cancer therapeutics and mechanisms (20 papers), MicroRNA in disease regulation (18 papers) and Drug Transport and Resistance Mechanisms (12 papers). Jan Stenvang collaborates with scholars based in Denmark, China and United States. Jan Stenvang's co-authors include Sakari Kauppinen, Morten Lindow, Susanna Obad, Andreas Petri, Jesper Wengel, Simon Fredriksson, Martin Lundberg, Erika Assarsson, Göran Holmquist and Johan Björkesten and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Genetics.

In The Last Decade

Jan Stenvang

91 papers receiving 5.3k citations

Hit Papers

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensit... 2014 2026 2018 2022 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability
    2014 1.1k citations Erika Assarsson, Martin Lundberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Stenvang Denmark 33 3.4k 2.1k 802 597 394 93 5.4k
Gaoliang Ouyang China 31 3.3k 1.0× 1.6k 0.8× 1.6k 2.0× 607 1.0× 441 1.1× 51 5.8k
Jie Zhou China 42 2.9k 0.9× 2.2k 1.0× 784 1.0× 523 0.9× 387 1.0× 104 5.0k
Juan Liu China 33 2.5k 0.7× 1.5k 0.7× 610 0.8× 837 1.4× 305 0.8× 185 4.7k
Gerolama Condorelli Italy 49 4.7k 1.4× 2.7k 1.3× 764 1.0× 592 1.0× 377 1.0× 122 6.9k
Jong In Yook South Korea 36 3.7k 1.1× 1.7k 0.8× 1.3k 1.6× 412 0.7× 280 0.7× 116 5.3k
August Vidal Spain 38 3.1k 0.9× 1.7k 0.8× 856 1.1× 535 0.9× 484 1.2× 110 5.2k
Piotr Rychahou United States 42 4.5k 1.3× 1.9k 0.9× 1.8k 2.3× 512 0.9× 482 1.2× 105 6.6k
Lin Chen China 41 4.0k 1.2× 2.6k 1.2× 1.4k 1.8× 1.4k 2.3× 432 1.1× 227 7.0k
Phillip Kantharidis Australia 31 2.6k 0.8× 1.3k 0.6× 506 0.6× 300 0.5× 303 0.8× 64 4.3k

Countries citing papers authored by Jan Stenvang

Since Specialization
Citations

This map shows the geographic impact of Jan Stenvang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Stenvang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Stenvang more than expected).

Fields of papers citing papers by Jan Stenvang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Stenvang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Stenvang. The network helps show where Jan Stenvang may publish in the future.

Co-authorship network of co-authors of Jan Stenvang

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Stenvang. A scholar is included among the top collaborators of Jan Stenvang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Stenvang. Jan Stenvang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noer, Julie B., Sune Boris Nygård, Ulrik Lademann, et al.. (2023). The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells. Molecular Oncology. 17(8). 1595–1612. 5 indexed citations
2.
3.
Semple, Susan J., Bevan Buirchell, Henrik Franzyk, et al.. (2021). Reversal of ABCG2/BCRP-Mediated Multidrug Resistance by 5,3′,5′-Trihydroxy-3,6,7,4′-Tetramethoxyflavone Isolated from the Australian Desert Plant Eremophila galeata Chinnock. Biomolecules. 11(10). 1534–1534. 9 indexed citations
4.
Huang, Peide, Fengyu Li, Zongchao Mo, et al.. (2021). A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer. Frontiers in Oncology. 11. 24 indexed citations
5.
Houlind, Kim Christian, Jan Stenvang, Lars Bundgaard, et al.. (2021). Identifying curriculum content for a cross-specialty robotic-assisted surgery training program: a Delphi study. Surgical Endoscopy. 36(7). 4786–4794. 14 indexed citations
6.
7.
Wiese, Michael, Michael Gajhede, Lasse Saaby, et al.. (2020). The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. Cells. 9(3). 613–613. 16 indexed citations
8.
Palshof, Jesper Andreas, Estrid Høgdall, Tim Svenstrup Poulsen, et al.. (2020). ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 21(14). 5027–5027. 8 indexed citations
9.
10.
Mirzaei, Hamed, Fatemeh Momeni, Aria Masoudifar, et al.. (2017). State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. Journal of Cellular Physiology. 233(2). 888–900. 102 indexed citations
11.
Stenvang, Jan, et al.. (2016). The volume regulated anion channel inhibitor NS3728 to enhance the cytotoxic effects of SN-38 in human colorectal cancer cells grown in vitro.. Journal of Clinical Oncology. 34(15_suppl). e23170–e23170. 1 indexed citations
12.
Kümler, Iben, Eva Balslev, Jan Stenvang, Nils Brünner, & Dorte Nielsen. (2015). A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. BMC Cancer. 15(1). 78–78. 8 indexed citations
13.
Jensen, Anders A., Niels F. Jensen, Lennart Bunch, et al.. (2015). The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 15(1). 411–411. 19 indexed citations
14.
Lademann, Ulrik, Peter Højrup, Morten Thaysen‐Andersen, et al.. (2014). Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells. Protein Expression and Purification. 101. 157–164. 8 indexed citations
15.
Lademann, Ulrik, Vibeke Jensen, Jan Stenvang, et al.. (2013). TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line. Tumor Biology. 34(2). 1161–1170. 3 indexed citations
16.
Thorsen, Stine Buch, Martin Lundberg, Andrea Villablanca, et al.. (2013). Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. Journal of Translational Medicine. 11(1). 253–253. 38 indexed citations
17.
Stenvang, Jan, Andreas Petri, Morten Lindow, Susanna Obad, & Sakari Kauppinen. (2012). Inhibition of microRNA function by antimiR oligonucleotides. PubMed. 3(1). 1–1. 435 indexed citations
18.
Stenvang, Jan, Marcel Smid, Søren Drud-Heydary Nielsen, et al.. (2012). Abstract P3-06-32: Topoisomerase 1 gene copy aberration is a frequent finding in clinical breast cancer samples. Cancer Research. 72(24_Supplement). P3–6. 2 indexed citations
19.
Stenvang, Jan, Asli Silahtaroglu, Morten Lindow, Joacim Elmén, & Sakari Kauppinen. (2008). The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Seminars in Cancer Biology. 18(2). 89–102. 151 indexed citations
20.
Stenvang, Jan & Jesper Wengel. (2004). LNA-antisense rivals siRNA for gene silencing.. University of Southern Denmark Research Portal (University of Southern Denmark). 7(2). 188–94. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gaoliang Ouyang Breakdown of academic impact, for papers by Jie Zhou Breakdown of academic impact, for papers by Juan Liu Breakdown of academic impact, for papers by Gerolama Condorelli Breakdown of academic impact, for papers by Jong In Yook Breakdown of academic impact, for papers by August Vidal Breakdown of academic impact, for papers by Piotr Rychahou Breakdown of academic impact, for papers by Lin Chen Breakdown of academic impact, for papers by Phillip Kantharidis
Rankless by CCL
2026